MIAMI, June 1, 2011 /PRNewswire/ -- Bio-Tissue, the industry leader in Ophthalmic tissue products, announced today that it has shipped over 7,500 ProKera® units since the product's inception. ProKera® is the only medical device that can provide wound healing to over 350,000 annual cases of patients afflicted with damaged ocular surfaces. ProKera® is a class II medical device composed of cryopreserved amniotic membrane tissue clipped into a thermoplastic ring set. "We are excited to be able to provide ProKera® to the patient community that is in dire need of this innovative technology," stated Amy Tseng, President, CEO, Bio-Tissue, Inc. "We are also encouraged by the support we have received to allow this procedure to be performed and reimbursed in the physician's office setting," concluded Tseng.
ProKera® combines the functionality of a symblepharon ring with the biologic actions of cryopreserved amniotic membrane to create a unique treatment option for patients presented with corneal abrasions, scarring, erosion, infectious disease and chemical/thermal burns. "ProKera® is a safe and effective product that allows me to provide my patients with unparalleled clinical results without the invasiveness of surgery," said Dr. George Rosenwasser of Central Pennsylvania Eye Institute. "In addition, the ProKera® device configuration enables easy insertion in the office, hospital bedside, or following other surgical procedures."
Bio-Tissue is the industry leader in ophthalmic tissue products and is engaged in the procurement, processing, storage, and distribution of cryopreserved human amniotic membrane. Bio-Tissue's patented CryoTek™ method ensures that the tissue retains biologic activity to promote wound healing as well as superior handling characteristics. Bio-Tissue is headquartered in Miami, FL and services customers shared with companies such as Alcon, Abbott Labs and Bausch & Lomb. For more information, please visit our website at www.biotissue.com
Copyright©2010 PR Newswire.
All rights reserved